Regeneron Eyes Another Pipeline Target: Arcalyst In Gout
This article was originally published in Pharmaceutical Approvals Monthly
Fresh from a success with the approval of Eylea for wet AMD, Regeneron has another target in sight: Arcalyst (rilonacept) for prevention of gout flares in patients initiating uric acid lowering therapy. FDA has accepted a supplemental BLA for the drug.
You may also be interested in...
Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.
Regeneron Lays Out Commercial Case For Arcalyst In Gout Flares To Investors; Convincing Payers May Be Challenge
During the biopharma's first ever investor day, management outlines early plans for the launch of Arcalyst for the prevention of gout flares.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.